GlassScriptPhysician profile
Christopher Allen Chin
NPI 1194776401
$1,293.60
in general payments reported to CMS, 2019-2025
12 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.93 · 2022: $22.10 · 2024: $386 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.13 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.31 | 2025 | Jardiance |
| Revance Therapeutics, INC. | $173.96 | 2025 | Daxi |
| Otsuka America Pharmaceutical, INC. | $147.09 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $124.99 | 2024 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $124.99 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $124.97 | 2024 | Vemlidy |
| Sanofi-Aventis U.S. LLC | $118.91 | 2024 | |
| Lilly USA, LLC | $116.65 | 2025 | Kisunla |
| Ars Pharmaceuticals Operations, INC. | $67.31 | 2025 | Neffy |
| Livanova USA, INC. | $25.05 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Pfizer INC. | $17.44 | 2024 | |
| Glaxosmithkline, LLC. | $16.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.